Fibrotic diseases manifest in various organs such as the liver, kidney, heart, pancreas, skin, and lungs. Given the exceptional therapeutic efficacy demonstrated by SBC101 in treating lung fibrosis, there is a strong indication for its potential applicability in addressing other fibrotic conditions. As a result, SapiensBio is actively pursuing the expansion of indications for SBC101. Recently, promising therapeutic effects on hepatic fibrosis have been confirmed through rigorous testing utilizing a human hepatic stellate cell model. Furthermore, preparations for a series of in vivo efficacy studies are currently underway